Clinical Trials of Adjuvant Trastuzumab

Randomized trial data from the advanced disease setting demonstrate that in women with HER2-overexpressing breast cancer, the combination of trastuzumab and chemotherapy — using either doxorubicin/cyclophosphamide or paclitaxel — results in improved progression-free and overall survival compared to the same chemotherapy given without trastuzumab. These encouraging results have led to a new generation of adjuvant trials evaluating a variety of chemotherapy regimens combined with trastuzumab. While no efficacy endpoints have been met, closely evaluated cardiac monitoring has not yet revealed dysfunction that would preclude continuing these trials. Almost all clinical research leaders currently advocate using adjuvant trastuzumab only in a clinical trial setting.

ASSESSMENT OF TRASTUZUMAB-ASSOCIATED CARDIAC EVENTS: NSABP-B-31 TREATMENT AND MAJOR SCHEDULE

Cardiac events (%) 4.28%

Cardiac toxicity — Geyer Jr CE. Presentation. — Charles E Geyer Jr, MD

SELECT PUBLICATIONS

Breast Cancer Res Treat 2004;88 Suppl 2:S10

Copyright © 2009 Research To Practice. All rights reserved. Poster information is for educational purposes only. Please see full prescribing information and protocols.